Skip to main content
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. — Investor Relations & Filings

Ticker · NRSN ISIN · IL0011809592 LEI · 254900UWMHXRH1IZPT20 US Manufacturing
Open in API
Filings indexed 281 across all filing types
Latest filing 2024-05-07 Regulatory Filings
Country IL Israel
Listing US NRSN

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com/

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about clinical trial data and is relatively short (2124 characters). The document states that the press release is furnished as an exhibit and incorporated by reference into registration statements. There are no detailed financial statements or comprehensive financial analysis present. The document primarily serves as a regulatory announcement of new information rather than a full financial report or earnings release. According to the rules, Form 6-K filings are best classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-07 English
Regulatory Filings 2024
Regulatory Filings
2024-04-25 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering. It includes information about the offering of ordinary shares, pre-funded warrants, and ordinary warrants, pricing, placement agent fees, risk factors, use of proceeds, dividend policy, and legal matters. The document is clearly a registration and offering document related to capital raising activities. It is not an annual report, earnings release, management discussion, or any other type of financial or governance report. The presence of terms like 'prospectus supplement', 'offering', 'placement agent', and detailed securities issuance information indicates this is a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2024-04-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by NeuroSense Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content details a securities purchase agreement, registered direct offering, issuance of shares and warrants, placement agent agreement, and related legal opinions. It is a regulatory filing reporting a capital raising transaction and related agreements. The document does not contain financial statements or detailed financial performance data, nor is it an earnings release or annual/interim report. It is not a proxy, voting result, or management change announcement. The document is a typical regulatory filing reporting a financing transaction and related agreements, consistent with the definition of Regulatory Filings (RNS). The document length is over 12,000 characters and contains detailed transaction information, not just an announcement of a report, so it is not a Report Publication Announcement (RPA). Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-04-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Investor Presentation Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It specifically mentions that it includes an updated presentation about the company's business, furnished as Exhibit 99.1. The text states that the presentation is summary information and will be made available on the investor relations website. The document length is short (2007 characters), and it primarily serves to furnish a presentation rather than containing detailed financial statements or comprehensive report content. According to the classification rules, a document that provides a presentation for investors focusing on financials, strategy, and market position should be classified as an Investor Presentation (IP). This is not an annual report, earnings release, or regulatory filing. Therefore, the appropriate classification is Investor Presentation (IP).
2024-04-10 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release about a collaboration but does not include detailed financial statements or substantive financial data. The document length is short (1693 characters), and it primarily serves as an announcement of a press release rather than a full report. According to the rules, such filings are best classified as Regulatory Filings (RNS) because they do not fit into other specific categories and are not full financial reports or detailed presentations.
2024-04-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.